Investigational drug · Phase 3
Ociperlimab
Also called: BGB-A1217
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Advanced Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
15
Any phase or sponsor naming "Ociperlimab"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ociperlimab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Advanced Malignancies
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ociperlimab" as an intervention, largest first.
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerPivotal-lookingTerminated
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04746924 · 669 participants · Start May 24, 2021 · Primary completion May 30, 2025
Drug: Tislelizumab; Ociperlimab and 2 more · For: Non-small Cell Lung Cancer; NSCLC
Sites: Fullerton, California; Los Angeles, California; Ocala, Florida · 218 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04047862 · 446 participants · Start Aug 15, 2019 · Primary completion Aug 7, 2024
Drug: Ociperlimab; Tislelizumab and 9 more · For: Locally Advanced and Metastatic Solid Tumors
Sites: Phoenix, Arizona; Fort Myers, Florida; Jacksonville, Florida · 65 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
- Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05014815 · 272 participants · Start Nov 16, 2021 · Primary completion Sep 4, 2024
Drug: Ociperlimab; Tislelizumab and 6 more · For: Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC); Nonsmall Cell Lung Cancer, Stage IIIB; Nonsmall Cell Lung Cancer, Stage IV
Sites: Los Angeles, California; Iowa City, Iowa; Las Vegas, Nevada · 64 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04693234 · 178 participants · Start Feb 15, 2021 · Primary completion Jun 16, 2022
Drug: Tislelizumab; Ociperlimab · For: Cervical Cancer
Sites: Panagyurishte, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 68 sites in all
- Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04952597 · 126 participants · Start Jul 15, 2021 · Primary completion Jul 26, 2023
Drug: Ociperlimab; Tislelizumab and 1 more · For: Limited Stage Small Cell Lung Cancer
Sites: Knoxville, Tennessee; Beijing, China; Lanzhou, China · 33 sites in all
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04732494 · 125 participants · Start Mar 31, 2021 · Primary completion Feb 1, 2023
Drug: Tislelizumab; Ociperlimab and 1 more · For: Esophageal Squamous Cell Carcinoma
Sites: Hefei, China; Quanzhou, China; Xiamen, China · 86 sites in all
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05577702 · 121 participants · Start Mar 8, 2023 · Primary completion Dec 13, 2024
Drug: Tislelizumab; Ociperlimab and 5 more · For: Non Small Cell Lung Cancer
Sites: Wuhu, China; Beijing, China; Fuzhou, China · 14 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04948697 · 94 participants · Start Aug 20, 2021 · Primary completion Feb 1, 2024
Drug: Ociperlimab; Tislelizumab and 1 more · For: Advanced Hepatocellular Carcinoma
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 28 sites in all
- A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerPivotal-lookingTerminated
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04866017 · 63 participants · Start Jun 17, 2021 · Primary completion Oct 17, 2023
Drug: Tislelizumab; Durvalumab and 2 more · For: Non Small Cell Lung Cancer
Sites: Bolivar, Missouri; Wollongong, Australia; Douglas, Australia · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Astragalus polysaccharide exerts anti-tumor effects associated with altered TIGIT-CD155 axis expression in Lewis lung carcinoma models.
Wang B, Wang P, Hu Z · Transl Cancer Res 2026
- AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
Lu S, Yu Y, Zhang J, et al. · J Immunother Cancer 2026
- Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study.
Wang F, Lin CY, Sun JM, et al. · Nat Commun 2026
- AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
Xing L, Kato T, Levy A, et al. · J Immunother Cancer 2026
- AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.
Socinski MA, Reck M, Paz-Ares L, et al. · J Thorac Oncol 2026
- AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Ren Z, Huang Y, Guo Y, et al. · Cancer Immunol Immunother 2026
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.